Elucidating T-oligo's Mechanism of Action as an Anticancer Therapeutic

A. Agnihotri and N. Puri
University of Illinois, Chicago, Illinois, United States

Poster stand number: W129

Keywords: T-oligo, G-quadruplex, FRET, acceptor photobleaching

In 2022, an estimated 99,780 new cases and 7,650 people are expected to die of melanoma. Despite several new treatment strategies, the 5-year overall survival rate of metastatic melanomas is only 27%. Telomeres have become a very desirable target for anti-cancer therapeutics as they are elongated by Telomerase mainly in cancer cells. T-oligo is a guanine rich oligonucleotide that is homologous to the 3’ telomere overhang. T-oligo binds to telomere associated proteins and prevents them from binding to telomeres inducing DNA damage responses in cancer cells through tumor suppressor proteins such as p53. Previous studies conducted in Dr. Puri’s lab have confirmed by NMR spectroscopy that T-oligo is known to form G-quadruplex structures. This study aims to understand the effect of T-oligo on the cell proliferation, uptake of fluorescently labeled T-oligo and detection of formation of G4 using FRET microscopy and acceptor photobleaching method in melanoma cells.